Bone demineralization, biochemical indices of bone remodeling, and estrogen replacement therapy in adults with Turner's syndrome.
The study centered on a controversy about whether long-term estrogen replacement therapy may ameliorate the osteoporosis seen in patients with Turner's syndrome. This study comprised 26 adult patients with Turner's syndrome (9 treated and 17 untreated or insufficiently treated) and 12 adult women with pure gonadal dysgenesis (8 untreated and 4 treated). A low bone density below -2 standard deviations from the age- and sex-matched predicted normal mean was documented by dual-photon absorptiometry of the lumbar spine in all the untreated and insufficiently treated patients, but only in 6 treated patients. The biochemical indices of bone resorption (urinary hydroxyproline excretion and plasma tartrate-resistant acid phosphatase activity), as well as osteoblastic function (serum osteocalcin and bone alkaline phosphatase isoenzyme), were significantly increased in untreated and insufficiently treated patients compared with treated patients. A significant negative correlation was found between biochemically documented osteoresorption and spinal bone mineral density corrected for age of the patients. Significant positive correlations were found between serum osteocalcin and bone alkaline phosphatase isoenzyme and between biochemical indices of bone resorption and formation. Although in the patients there was an evidence of a high bone remodeling rate, the rate of bone mass loss seemed to be low, comparable with that seen in oophorectomized women who had already passed their accelerated phase of bone loss. The results indicate that long-term hormonal replacement therapy is justified in gonadal dysgenesis, regardless of the karyotype of the patient, to prevent further bone mass loss.
Stĕpán
J J
JJ
Department of Medicine, Charles University Faculty of Medicine, Prague, Czechoslovakia.
Musilová
J
J
Pacovský
V
V
D000135:Acid Phosphatase / Q000378:metabolism; D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood; D001861:Bone Regeneration / Q000187:drug effects*; D001862:Bone Resorption / Q000187:drug effects; D001842:Bone and Bones / Q000378:metabolism*; D002135:Calcium-Binding Proteins / Q000097:blood; D004967:Estrogens / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D007527:Isoenzymes / Q000097:blood; D008903:Minerals / Q000378:metabolism*; D015675:Osteocalcin; D014424:Turner Syndrome / Q000188:drug therapy* / Q000378:metabolism
D002135:Calcium-Binding Proteins; D004967:Estrogens; D007527:Isoenzymes; D008903:Minerals; D015675:Osteocalcin; D000469:Alkaline Phosphatase; D000135:Acid Phosphatase; D006909:Hydroxyproline